Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Damien Vaccines
- Ownership
- Private
- Development stage
- Other
01
Overview
Damien Vaccines is a biotechnology company focused on the development of next-generation vaccines for neglected tropical diseases and global infectious threats, specifically tuberculosis and leprosy. The company leverages advanced recombinant protein technology and novel adjuvant systems to enhance immune responses in populations where traditional vaccines have shown limited efficacy. Damien Vaccines aims to address the significant global health burden of mycobacterial infections through targeted research and development. Their work is often characterized by a commitment to providing accessible and effective immunization solutions for underserved regions.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineRecombinant proteinAdjuvant
- Industry
- Biotech
02
Partnerships
Damien FoundationInfectious Disease Research Institute (IDRI)
Beyond the preview
Go deeper on Damien Vaccines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Damien Vaccines.